Opus Genetics, Inc. (IRD)
| Market Cap | 287.75M +385.2% |
| Revenue (ttm) | 11.98M -12.2% |
| Net Income | -106.93M |
| EPS | -1.42 |
| Shares Out | 71.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,017,102 |
| Open | 4.610 |
| Previous Close | 4.640 |
| Day's Range | 4.015 - 4.610 |
| 52-Week Range | 0.901 - 5.810 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 10.47 (+159.8%) |
| Earnings Date | May 12, 2026 |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $10.47, which is an increase of 159.80% from the latest price.
News
Opus Genetics registers to sell 2.68M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 2.68M shares of common stock. The company is not selling any…
Opus Genetics Registration statement: Registration filing
Opus Genetics filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Opus Genetics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Opus Genetics (IRD) with a Buy rating and $16 price target
Opus Genetics management to meet with Citizens
Meeting to be held in Minneapolis on June 11 hosted by Citizens.
Opus Genetics Transcript: Jefferies Global Healthcare Conference 2026
Seven gene therapy programs for inherited retinal diseases are advancing rapidly, with pivotal data for LCA5 and first-in-human data for BEST1 expected soon. Early clinical results show dramatic vision improvements, and a strong financial position supports progress toward multiple approvals.
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Slides: Investor presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on May 30, 2026.
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bli...
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics initiated with an Outperform at Leerink
Leerink initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target Opus is a clinical-stage company developing gene therapies for inherited retinal disorders, the analyst...
Opus Genetics initiated with an Outperform at Leerink
Leerink analyst Lili Nsongo initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target
Opus Genetics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The company is advancing a robust gene therapy pipeline for inherited retinal diseases, with multiple programs entering the clinic and key data readouts expected in 2024. Regulatory designations and a strong cash position support progress toward pivotal trials and potential non-dilutive funding.
Opus Genetics Slides: Corporate presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics price target lowered to $11 from $12 at Citizens
Citizens lowered the firm’s price target on Opus Genetics (IRD) to $11 from $12 and keeps an Outperform rating on the shares. Recent ARVO data continue to support OPGx-LCA5’s durable…
Opus Genetics reports Q1 EPS (75c), consensus (14c)
Reports Q1 revenue $2.16M, consensus $2.93M. “With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics (IRD) is entering a defining stretch where we believe our…
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepte...
Opus Genetics Quarterly report: Q1 2026
Opus Genetics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and I...
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide...
Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program
Opus Genetics (IRD) announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the FDA Rare Disease Evidence Principles, or RDEP, program. OPGx-LCA5 is a potential...
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics price target raised to $10 from $9 at B. Riley
B. Riley raised the firm’s price target on Opus Genetics (IRD) to $10 from $9 and keeps a Buy rating on the shares.
Opus Genetics initiated with an Outperform at Citizens
Citizens initiated coverage of Opus Genetics (IRD) with an Outperform rating and $12 price target The company is developing a portfolio of AAV-based gene therapies for inherited retinal diseases, with...
Opus Genetics management to meet with Piper Sandler
Meeting to be held in New York on April 28 hosted by Piper Sandler.